Investigating how amino-terminal acetylation of proteins affects health and disease.
Official title: Amino-terminal acetylation of proteins in mammalian biology and disease
Funded at Institute for Basic Res in Dev Disabil · NIH-10669690 · Data updated 2026-11-12
This study is looking at how a specific protein change called amino-terminal acetylation might affect health and diseases like Alzheimer's and some cancers, with the goal of finding new ways to treat these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Basic Res in Dev Disabil NIH-funded |
| Lab location | 1 site (Staten Island, United States) |
| Project start | September 1, 2019 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $398,907 |
| NIH project number | 5R35GM133408-05 |
| Project ID | NIH-10669690 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or related neurodegenerative conditions, as well as those with specific genetic mutations linked to protein acetylation.
✕Less likely to help
Patients with conditions unrelated to protein acetylation or those who do not have a genetic predisposition to the diseases being studied may not benefit from this research.
What this research studies
This research focuses on understanding the role of amino-terminal acetylation (NTA) in mammalian biology and its implications for diseases such as Alzheimer's and certain cancers. The study aims to explore how this protein modification influences cellular functions and disease mechanisms, using both cell culture techniques and in vivo models. By examining the effects of NTA on protein stability and activity, the research seeks to uncover potential therapeutic targets for conditions linked to protein misregulation.
Why it matters
Potential benefit: If successful, this research could lead to new insights and treatments for diseases like Alzheimer's and certain cancers by targeting protein modifications.
How similar studies have gone: While the specific focus on amino-terminal acetylation is relatively novel, there have been successful studies exploring other protein modifications that have led to significant advancements in understanding disease mechanisms.
Where this research is happening
-
Institute for Basic Res in Dev Disabil
Staten Island, United States Active
Researchers
- Principal investigator: Lyon, Gholson — Institute for Basic Res in Dev Disabil
- Study coordinator: Lyon, Gholson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.